• Mary A Anderson, Rory Bennett, Xavier Badoux, Giles Best, Nicole Chia, Tara Cochrane, Gavin Cull, Kyle Crassini, Rosemary Harrup, Sharon Jackson, Bryone Kuss, Masa Lasica, Thomas E Lew, Paula Marlton, Stephen Opat, Emma Palfreyman, Mark N Polizzotto, Sumita Ratnasingam, John F Seymour, Asha Soosapilla, Dipti Talaulikar, Constantine S Tam, Robert Weinkove, Joel Wight, and Stephen P Mulligan.
• Department of Clinical Haematology, The Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
• Intern Med J. 2023 Sep 1; 53 (9): 167816911678-1691.

AbstractChronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The availability of next-generation sequencing and measurable residual disease assessment by flow cytometry allow for advanced prognostication and response assessments. Novel therapies, including inhibitors of Bruton's tyrosine kinase (BTKi) and B-cell lymphoma 2 (BCL2) inhibitors, have transformed the treatment landscape for both treatment-naïve and relapsed/refractory disease, particularly for patients with high-risk genetic aberrations. Recommendations regarding appropriate supportive management continue to evolve, and special considerations are required for patients with CLL with respect to the global SARS-CoV-2 pandemic. The unique funding and treatment environments in Australasia highlight the need for specific local guidance with respect to the investigation and management of CLL. This consensus practice statement was developed by a broadly representative group of ANZ experts in CLL with endorsement by peak haematology bodies, with a view to providing this standardised guidance.© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.

14 keywords...

hide…